Arrowhead Pharmaceuticals’ Post

Results of the long-term results of the post-market phase of BeAT-HF study now publishsed: The study showed that despite the fact that Baroreflex activation therapy did not result in a significant difference in the composite primary endpoint, CV mortality and HF morbidity, or the individual components of the primary endpoints compared with control. Both long-term measures of safety and symptomatic improvement favoured the BAT group, were durable over time, and sustainable in the extent of their effects. In addition, results of the all-cause mortality and the hierarchical win-ratio analyses favoured the BAT group. The totality of evidence obtained during the post-market phase of the BeAT-HF trial indicated that BAT provided safe, effective, and sustainable improvements in HFrEF patient's functional status, 6MHWD and QOL. These findings further support the use of this novel device therapy in heart failure patients with reduced EF who are still symptomatic despite maximally tolerated GDMT and who are not candidate for CRT therapy.

https://lnkd.in/gjGm_7Jm Article title: A lower limb BOLD-MRI tissue perfusion protocol correlate to clinical disease stage, objective functional limitations, and health-related quality of life in patients with peripheral arterial occlusive disease Author(s): Joakim Nordanstig*; Kristina Törngren; Jonathan Arvidsson; Stefanie Eriksson; Mårten Falkenberg; Åse Johnsson; Kerstin Lagerstrand Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: While peripheral artery occlusive disease (PAOD) by large is a clinical diagnosis, further characterization of the ischemic state, procedural planning, and longitudinal follow-up after revascularisation are mainly based on imaging that delineates the arterial vasculature. Although several potential techniques have been suggested [1], there is still no clearly established imaging technique that directly quantifies the crucial PAOD pathophysiological process-tissue perfusion in the lower limb. #PeripheralArterialDisease #IntermittentClaudication #BOLDMRI #TissuePerfusion #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

https://lnkd.in/gjXB2Eu4 Article title: Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial Author(s): Mohammed Habib* Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Background: We compared the angiotensin receptor–neprilysin inhibitor LCZ696 (sacubitril/valsartan) with enalapril in patients who had nonischemic heart failure with a reduced ejection fraction. Methods: In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Our latest publication in the Journal of Clinical Case Reports and Images sheds light on a groundbreaking intervention for left main coronary artery chronic total occlusion (LMCA CTO). Traditionally, coronary artery bypass grafting has been the go-to method for revascularization, but our study presents evidence that percutaneous coronary intervention (PCI) could be a viable alternative for select high-risk patients. Using advanced techniques and state-of-the-art equipment, our team successfully recanalized the occluded LMCA and associated arteries, resulting in remarkable improvements in heart function. After just two months, patients experienced a significant increase in ejection fraction and a notable decrease in Congestive Heart Failure functional class. This study underscores the importance of careful patient selection and appropriate procedural techniques in achieving successful outcomes with PCI for LMCA CTO lesions. For more details on our findings, check out the full article here: https://lnkd.in/gPr-W9Fi Stay tuned for more updates on groundbreaking research in cardiovascular medicine! #Cardiology #Research #HeartHealth 🫀

#RESHAPE_HF2 and #MATTERHORN and #TRI_FR are 3 new investigator initiated studies (IIS) for mitral and tricuspid valve repair therapies that were presented as late-breaking data #ESCcongress in 2024 of the European Society of Cardiology: the RESHAPE-HF2, MATTERHORN, Tri-FR trials. These clinical outcomes represent milestones for Mitral and Tricuspid therapies demonstrating safety and efficacy with #MitraClip and #TriClip as #TEER interventions Watch Univ.-Prof.Dr. Ralph Stephan von Bardeleben from Universitätsmedizin Mainz #TeamUM #Mainz #Germany and Prof. Dr. erwan donal CHU #Rennes #France giving their perspective on these important randomized clinical #trial (#RCT) results: https://lnkd.in/eZuAnzMj

Dr. Toleva on Medis QFR® at TCT 2023 – Microvascular dysfunction assessment   Focusing on non-obstructive coronary arteries, the presentation of Dr. Olga Toleva at TCT 2023 highlights the challenges in microvascular dysfunction assessment and introduces promising advancements in non-wire-based techniques.   Dr. Toleva shows the potential of Medis QFR®, a non-wire-based technique, to streamline assessments without wire manipulation or medications. In her presentation, Dr. Toleva also discussed current techniques involving intravenous adenosine, coronary flow reserve, and index of microvascular resistance (IMR), acknowledging their time-intensive nature.   Furthermore, Dr. Toleva explored the clinical applications of this technique in various coronary conditions like stable angina, STEMI, and Tako-Tsubo. This presentation at TCT 2023 marks a significant step forward in interventional cardiology, offering a glimpse into a future where microvascular dysfunction assessment is simpler, quicker, and more patient-friendly.   . . . #TCT2023 #CardiologyInnovation #MicrovascularAssessment

https://lnkd.in/gitQ9EMR Article title: FMTVDM-Finally Opens the Doorway from Qualitative to Quantitative Measurement and Treatment of Heart Disease Author(s): Richard M Fleming*; Matthew R Fleming Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Diagnostic determination of coronary artery disease has primarily relied upon qualitative image interpretation and tests of minimal measureable value. The introduction of the first measureable test dates back to the late 1890s following its presentation by Willem Einthoven at a Dutch Medical Association Conference in 1893-the electrocardiogram. While the electrocardiogram provides millimeter changes on paper-these changes do not translate into measureable myocardial consequence. #FMTVDM #HeartDisease #Qualitative #Quantitative #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

Today, at the European Society of Cardiology Congress, Global Heart Hub will present a poster from their study: Insights from the Patients living with Elevated Cholesterol (IPEC). It is the patient perspective being presented by patients to physicians about the importance of decision-making when patients are first diagnosed with hypercholesterolemia. Delighted to see the patient voice present at medical congresses with such relevance! #patientengagement #patientvoice #patientdata #globalhearthub #ipec

Thrilled to announce that our abstract titled 'Insights into retroperitoneal hemorrhage management: Results from a tertiary cardiovascular center prospective cohort' has been accepted for poster presentation at the #European_Society_of_Cardiology Congress 2024 in #London! #ESC is the world leader in the discovery and dissemination of best practice guidelines in cardiovascular medicine and, alongside the American Heart Association (AHA), advances the cutting edge of knowledge and provides trustworthy diagnostic and management guidelines in the field of cardiology. Utilizing #data_analytics, we analyzed approximately 90,000 patients undergoing #cardiovascular_intervention over an 8-year interval, identifying the cases of #retroperitoneal_hemorrhage (RPH) and comprehensively evaluated both conservative and interventional management approaches, bridging crucial gaps in current guidelines. Special thanks to Dr. Parham Sadeghipour to directing this research and providing valuable coresspondence. #ESC #ESC2024 #European_Society_of_Cardiology #CardiovascularMedicine #London #DataAnalytics

Coinciding with our recent presentation at the European Society of Cardiology Congress in London, we’re delighted to share the detailed findings in JACC Journals' Journal of the American College of #Cardiology from our Phase III trial testing the novel, low-dose, triple combination candidate for the treatment of #hypertension, GMRx2, against placebo.   The trial, conducted in Australia, Nigeria, Sri Lanka, UK and the US, examined the difference between GMRx2 and placebo in home-measured #bloodPressure change from randomization to week 4. GMRx2 significantly improved home- and clinic-measured blood pressure and control rates, in both half- and quarter-doses. Tolerability was good, with no increase in withdrawal from treatment due to adverse events. Learn more: https://lnkd.in/eW78_7wG #biotech #clinicalTrials #clinicalResearch #drugDevelopment